Recent Survey Highlights Overwhelming Support Among NZ Palliative Care Physicians
A groundbreaking survey conducted among 93 palliative care physicians across New Zealand and Australia has revealed significant enthusiasm for advancing research into psychedelic-assisted therapies for patients facing life-threatening illnesses. Published in early 2026, the study found that 88% of respondents support further clinical investigations into substances like psilocybin from magic mushrooms and MDMA, commonly known as ecstasy, to alleviate existential distress at the end of life. Notably, 75% disagreed with the notion that these psychedelics are inherently unsafe and should be prohibited for medical purposes, underscoring a shift in professional attitudes towards these once-stigmatized compounds.
This cross-sectional analysis, led by researchers including those affiliated with New Zealand's academic institutions, captures the evolving landscape where traditional palliative interventions often fall short in addressing profound psychological suffering such as anxiety, depression, and fear of death. Respondents highlighted the potential of psychedelic-assisted therapy (PAT), a structured approach combining low or therapeutic doses of psychedelics with psychotherapy, to foster meaningful psychological breakthroughs.
Defining Psychedelic-Assisted Therapy in the Palliative Context
Psychedelic-assisted therapy involves administering substances like lysergic acid diethylamide (LSD), psilocybin, or 3,4-methylenedioxymethamphetamine (MDMA) under controlled clinical conditions, paired with preparatory and integrative psychotherapy sessions. In palliative care, which focuses on improving quality of life for patients with serious, incurable illnesses, PAT targets 'existential distress'—a cluster of symptoms including demoralization, loss of meaning, and anticipatory grief that conventional antidepressants and counseling may not fully resolve.
The process typically unfolds in three phases: preparation to set intentions and build rapport; the dosing session, lasting 6-12 hours where patients experience altered states of consciousness; and integration to process insights. New Zealand universities have been at the forefront, adapting these protocols to local cultural contexts, including Māori perspectives on healing.
University of Auckland Leads with LSD Microdosing Trials
The University of Auckland has emerged as a hub for innovative psychedelic research, particularly through trials exploring LSD microdosing for advanced cancer patients. Led by PhD candidate Lisa Reynolds and supervised by academics like Professor David Menkes, the LSDDEP2 trial is a randomized, double-blind study testing repeated low doses (8 micrograms) of LSD against placebo over several weeks. Early feasibility data indicate improved mood and reduced anxiety without significant adverse effects.
Aiming for 50% Māori participation, this trial addresses health inequities, reflecting Auckland's commitment to culturally responsive research. Participants report enhanced wellbeing and connectedness, aligning with the recent physician survey's call for expanded studies. The university's Neuropharmacology Research Group continues to pioneer, securing Health Research Council funding for these efforts.
Complementing this, Auckland is running an MDMA-assisted therapy trial for patients with advanced cancer, evaluating high-dose sessions to mitigate end-of-life anxiety. These initiatives position the university as a leader in translating global psychedelic findings into Aotearoa New Zealand's healthcare system.
University of Otago's Psilocybin and MDMA Initiatives
At the University of Otago, the PARTING trial represents a bold step: an open-label pilot using psilocybin-assisted psychotherapy for cancer-related prolonged grief disorder (PGD). Recruiting around 15 participants, it combines a single moderate dose of psilocybin (25mg) with supportive therapy to help process bereavement and restore meaning. Principal investigator Dr. Leah Beesley notes promising preliminary outcomes in reducing grief intensity.
Otago also supports an MDMA trial for terminal cancer patients struggling with depression, funded by philanthropist Paul Adams. These projects underscore the university's role in building evidence for PAT, with researchers emphasizing rigorous safety protocols and psychological preparation to maximize therapeutic potential while minimizing risks like transient anxiety during sessions.
Māori Perspectives and Cultural Integration in Research
New Zealand's universities are prioritizing tikanga Māori in psychedelic research. A qualitative study from the University of Auckland explored Māori healthcare professionals' views, revealing cautious optimism tempered by concerns over historical trauma and the need for kaupapa Māori frameworks. Participants advocated for community-led trials to ensure therapies align with indigenous healing practices, avoiding colonial impositions.
This culturally attuned approach is evident in Auckland's LSD trial's equity focus and Otago's holistic integration plans. Such efforts not only enhance research validity but also foster trust, crucial for equitable access in palliative care where Māori face disproportionate cancer burdens.
Global Evidence Bolstering NZ's Research Momentum
International trials provide a robust foundation for New Zealand's work. Johns Hopkins' landmark psilocybin studies showed single doses yielding sustained reductions in end-of-life anxiety for 80% of cancer patients, with effects lasting months. Similarly, MDMA trials for PTSD have FDA breakthrough status, suggesting parallels for palliative distress.
In Australia, psilocybin is approved for treatment-resistant depression, paving the way for cross-Tasman collaboration. NZ physicians' survey aligns with these trends, with 82% favoring clinical trials, signaling readiness for larger, multi-site university-led studies.
Read the full Australasian physicians survey hereNavigating Regulations and Ethical Considerations
New Zealand's Misuse of Drugs Act classifies psychedelics as Class A substances, but special approvals via the Medicines Access route enable clinical use since 2023 for psilocybin in depression. Universities navigate stringent ethics reviews, emphasizing informed consent, set-and-setting optimization, and post-session support to mitigate rare risks like hallucinogen persisting perception disorder.
The recent survey notes logistical barriers like funding and training, yet 88% clinician support could spur policy evolution, potentially mirroring Australia's SAS-B pathway.
Challenges, Safety Profiles, and Risk Mitigation
While promising, PAT isn't risk-free. Acute effects include nausea, elevated blood pressure, and challenging psychological experiences ('bad trips'), screened via cardiac and psychiatric assessments. Long-term, no evidence of addiction or cognitive impairment in controlled settings. Universities prioritize multidisciplinary teams—psychiatrists, psychologists, nurses—for safety.
Contraindications include schizophrenia history; ongoing monitoring ensures participant wellbeing, as in Auckland's trials reporting high tolerability.
Photo by Usman Yousaf on Unsplash
Future Outlook: Expanding University-Led Trials
With physician backing and active trials, NZ universities eye Phase III studies and combination therapies. Potential integration into palliative guidelines could transform end-of-life care, reducing opioid reliance and enhancing dignity. Funding from HRC and philanthropists will be pivotal.
Collaborations with iwi and international partners promise culturally safe, evidence-based advancements.
Implications for Higher Education and Research Careers
NZ's psychedelic surge elevates universities' roles in translational medicine, attracting global talent. Programs in pharmacology, psychology, and Māori health at Auckland and Otago offer PhD opportunities in PAT, fostering interdisciplinary careers. As demand grows, higher ed must scale training, positioning NZ as a psychedelic research leader.
